Semaglutide raw material is a new generation of GLP-1 (glucagon like peptide-1) analog developed by Daminol and NovoNordisk. It is a long-term dosage form developed based on the basic structure of Lilalutide. Ozempic reduces blood sugar by increasing the action time of GLP-1 (a class of protein hormones) in the human body and promoting insulin secretion (especially for type 2 diabetes), thereby inhibiting appetite Reduce food intake.
The Legend of the Divine Medicine for Losing Weight
Studies have proved that overweight/obese diabetes patients lose 5%~10% of their weight, blood pressure, blood sugar, low-density lipoprotein cholesterol, triglycerides can be reduced, high-density lipoprotein cholesterol is increased, and cardiovascular risk of patients is reduced. For drug weight loss, the US FDA has approved a total of 5 types of weight loss drugs, including Saxenda. Liraglutide raw powder is a glucagon like peptide-1 (GLP-1) analogue that not only lowers blood sugar, but also has cardiovascular protective effects. Compared to Victoza, Semeglutide has a longer fatty chain and increased hydrophobicity, but Sermaglutide is modified with short chain PEG, greatly enhancing its hydrophilicity. After modification, PEG can not only tightly bind to albumin, mask the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, extend biological half-life, and achieve the effect of long circulation.
"After stopping medication, weight will rebound, may be dependent on it"
V-9-M cholecystokinin nonapeptide raw material is not applicable to normal or emaciated type 2 diabetes! " A doctor emphasized that Semaglutide (H-7894.0001) should be used for weight loss in patients with simple obesity. This is a super adaptive medication (beyond the scope of use in the drug manual), requiring examination of relevant indicators such as the pancreas and thyroid gland, and using it under the guidance of a doctor. The use of the drug by healthy people with normal body shape or the private increase of the dosage by diabetes patients are abuse. "Gastrointestinal discomfort and hypoglycemia are only normal side effects of medication. If they are severe, they can induce acute pancreatitis or lead to endocrine system disorders." In fact, Wegovy, which is approved abroad for the treatment of obesity, and Ozempic, which is popular in China, are not the same in specifications and dosage, although the ingredients are both Cholecystokinin Precursor (24-32).
The information in this article comes from the Internet and is not used as treatment advice or investment advice. If this article has an impact on your rights and interests or is interested in this product, please contact us in time so that we can provide you with more help